Literature DB >> 2550838

Effect of histamine depletion on circadian variations of corticotropin and corticosterone in rats.

N Itowi1, A Yamatodani, R Cacabelos, M Goto, H Wada.   

Abstract

The effects of cerebral histamine depletion induced by alpha-fluoromethylhistidine (FMH) on corticotropin (ACTH) and corticosterone secretions were examined. Neither acute nor chronic FMH treatment altered the corticoadrenal responses to three types of stress: transposition, immobilization and water immersion. And exposure to stress did not affect the hypothalamic content of histamine. However, chronic intracerebral treatment with FMH had a significant effect on the circadian rhythm of the plasma corticosterone (CS) level in rats. Namely, it caused a marked attenuation of the amplitude of the peaks of the CS level resulting in an almost arrhythmic state. The maximum differences between FMH treated and untreated groups were seen at 8.00 and 20.00 h, the times when the illumination condition changed (light onset 8.00 h). This treatment with FMH also had a similar effect on the plasma ACTH concentration; namely the plasma ACTH level in the saline treated group was lower than that of the FMH-treated group at light onset and higher than the latter at dark onset, but was similar to the latter at other sampling points. These results indicate the histaminergic modulation of the circadian rhythm of hormonal secretion of the adrenal cortex and show that this phenomenon is mediated through the central nervous system by an influence on the rhythm of hypophyseal ACTH secretion possibly through alteration in the concentration of corticotropin-releasing factor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550838     DOI: 10.1159/000125220

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  2 in total

1.  On the Role of Histamine Receptors in the Regulation of Circadian Rhythms.

Authors:  Stanislav V Rozov; Tarja Porkka-Heiskanen; Pertti Panula
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

2.  Possible use of a H3R antagonist for the management of nonmotor symptoms in the Q175 mouse model of Huntington's disease.

Authors:  Daniel S Whittaker; Huei-Bin Wang; Dawn H Loh; Roger Cachope; Christopher S Colwell
Journal:  Pharmacol Res Perspect       Date:  2017-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.